As indicated by our result, SLC35A2 expression exhibited significantly positive associations with TMB in STAD, revealing the higher potential of patients to benefit from tumor immunotherapy in line with the higher expression of SLC35A2 in STAD. The gene discussed is SLC35A2; the disease is neoplasm.